PALO ALTO, Calif., June 16 /PRNewswire/ -- Alexza Molecular Delivery Corporation ("Alexza") announced today that James V. Cassella, PhD, has joined the company as Senior Vice President, Research & Development. Dr. Cassella is a 15-year industry veteran and will have primary responsibility for Alexza's R&D organization. Dr. Cassella was most recently SVP of Clinical Research and Development at Neurogen Corporation, where he had overall responsibility for clinical development, drug regulatory affairs, safety and government relations. Dr. Cassella was a founding member of the scientific team, joining the company in 1989 as a Senior Scientist. Prior to joining Neurogen, Dr. Cassella was an Assistant Professor and first full-time faculty in the Neuroscience Program at Oberlin College. Dr. Cassella completed a postdoctoral fellowship at the Yale University School of Medicine, Department of Psychiatry. He received a PhD in Physiological Psychology from Dartmouth College and a BA from the University of New Haven.
"I am extremely pleased to welcome Jim to our Alexza management team," said Thomas B. King, President and CEO. "Jim's passion and contributions to the industry, coupled with his expertise in clinical research and development, make him an ideal leader for our R&D organization as we proceed with our aggressive plans in product development."
"I am very excited about all of the product development opportunities in Alexza's portfolio and look forward to bringing novel products into the clinic with the excellent team of scientists, engineers and staff," said Dr. Cassella. "I believe Alexza's Staccato(TM) technology has broad applicability and the research group will continue to identify new product ideas to grow our internal product pipeline."
Alexza was co-founded by biotechnology and drug delivery pioneer, Dr. Alejandro Zaffaroni. Alexza is a specialty pharmaceutical company developing products using the company's core platform, Staccato technology. The Staccato technology enables the rapid onset of therapeutic effect of many small molecule drugs as well as patient titration to the lowest effective dose to better treat acute and intermittent conditions. In addition to developing its own pipeline, focusing initially on central nervous system indications representing more than $17 billion in annual U.S. sales, the company plans to also strategically partner its technology with pharmaceutical companies.
Alexza Molecular Delivery Corporation
CONTACT: Thomas B. King, President & CEO of Alexza Molecular DeliveryCorporation, +1-650-687-3902